[HTML][HTML] A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet
G D'Errico, HL Machado, B Sainz - Clinical and translational medicine, 2017 - Springer
Immunotherapy is the new trend in cancer treatment due to the selectivity, long lasting
effects, and demonstrated improved overall survival and tolerance, when compared to …
effects, and demonstrated improved overall survival and tolerance, when compared to …
[HTML][HTML] Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
AA Inamdar, A Goy, NM Ayoub, C Attia, L Oton… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Despite advances in the development of clinical agents for treating Mantle Cell Lymphoma
(MCL), treatment of MCL remains a challenge due to complexity and frequent relapse …
(MCL), treatment of MCL remains a challenge due to complexity and frequent relapse …
[HTML][HTML] Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo
Z Chen, L You, L Wang, X Huang, H Liu, JY Wei… - Journal of Experimental …, 2018 - Springer
Background Exosomes derived from tumor cells (TEXs) are involved in both immune
suppression, angiogenesis, metastasis and anticancer stimulatory, but the biological …
suppression, angiogenesis, metastasis and anticancer stimulatory, but the biological …
[HTML][HTML] A non-interventional clinical trial assessing immune responses after radiofrequency ablation of liver metastases from colorectal cancer
MW Löffler, B Nussbaum, G Jäger… - Frontiers in …, 2019 - frontiersin.org
Background: Radiofrequency ablation (RFA) is an established treatment option for
malignancies located in the liver. RFA-induced irreversible coagulation necrosis leads to the …
malignancies located in the liver. RFA-induced irreversible coagulation necrosis leads to the …
[HTML][HTML] DC subsets regulate humoral immune responses by supporting the differentiation of distinct Tfh cells
To determine the contribution of skin DC subsets in the regulation of humoral immunity, we
used a well-characterized antigen targeting system to limit antigen availability and …
used a well-characterized antigen targeting system to limit antigen availability and …
[HTML][HTML] STxB as an antigen delivery tool for mucosal vaccination
E Tartour, L Johannes - Toxins, 2022 - mdpi.com
Immunotherapy against cancer and infectious disease holds the promise of high efficacy
with minor side effects. Mucosal vaccines to protect against tumors or infections disease …
with minor side effects. Mucosal vaccines to protect against tumors or infections disease …
Superiority in rhesus macaques of targeting HIV-1 Env gp140 to CD40 versus LOX-1 in combination with replication-competent NYVAC-KC for induction of Env …
G Zurawski, X Shen, S Zurawski, GD Tomaras… - Journal of …, 2017 - Am Soc Microbiol
We compared the HIV-1-specific immune responses generated by targeting HIV-1 envelope
protein (Env gp140) to either CD40 or LOX-1, two endocytic receptors on dendritic cells …
protein (Env gp140) to either CD40 or LOX-1, two endocytic receptors on dendritic cells …
[HTML][HTML] Dendritic cells in the cross hair for the generation of tailored vaccines
L Gornati, I Zanoni, F Granucci - Frontiers in immunology, 2018 - frontiersin.org
Vaccines represent the discovery of utmost importance for global health, due to both
prophylactic action to prevent infections and therapeutic intervention in neoplastic diseases …
prophylactic action to prevent infections and therapeutic intervention in neoplastic diseases …
Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy
ABSTRACT Cyclin dependent kinase 4/6 inhibitors (CDK4/6i) lead to cell-cycle arrest but
also trigger T cell-mediated immunity, which might be mediated by changes in human …
also trigger T cell-mediated immunity, which might be mediated by changes in human …
Drug discovery and therapeutic delivery for the treatment of B and T cell tumors
R Stephenson, A Singh - Advanced drug delivery reviews, 2017 - Elsevier
Hematological malignancies manifest as lymphoma, leukemia, and myeloma, and remain a
burden on society. From initial therapy to endless relapse-related treatment, societal burden …
burden on society. From initial therapy to endless relapse-related treatment, societal burden …